Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients

World Journal of Gastroenterology

Volumn 20, Issue 25, 2014, Pages 8195-8200

  Chen, Gong Ying ^a   Zhu, Meng Fei ^a   Zheng, Da Liang ^b   Bao, Yan Ting ^b   Wang, Jie ^a   Zhou, Xiang ^b   Lou, Guo Qiang ^a  

^a HANGZHOU NORMAL UNIVERSITY   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Baseline; Chronic hepatitis B; Hepatitis B surface antigen; Pegylated interferon 2b; Virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B (E) ANTIGEN; HEPATITIS B SURFACE ANTIGEN; PEGINTERFERON ALPHA2B; UNCLASSIFIED DRUG; VIRUS DNA; ALPHA INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT RESPONSE; BLOOD; DRUG EFFECTS; GENETICS; HEPATITIS B, CHRONIC; IMMUNOLOGY; PREDICTIVE VALUE; REMISSION; TIME; TREATMENT OUTCOME; VIRUS LOAD; ANTIBODY TITER; ANTIVIRAL THERAPY; BLOOD SAMPLING; CHRONIC HEPATITIS B; MONOTHERAPY; NONHUMAN; POLYMERASE CHAIN REACTION; SEROCONVERSION;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84903952353     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i25.8195     Document Type: Article

References (26)

1. Mohamed R, Ng CJ, Tong WT, Abidin SZ, Wong LP, Low WY. Knowledge, attitudes and practices among people with chronic hepatitis B attending a hepatology clinic in Malaysia: a cross sectional study. BMC Public Health 2012; 12: 601 [PMID: 22856889 DOI: 10.1186/1471-2458-12-601]
2. Liaw YF. Impact of therapy on the long-term outcome of chronic hepatitis B. Clin Liver Dis 2013; 17: 413-423 [PMID: 23905813 DOI: 10.1016/j.cld.2013.05.005]
3. Tujios SR, Lee WM. Update in the management of chronic hepatitis B. Curr Opin Gastroenterol 2013; 29: 250-256 [PMID: 23519135 DOI: 10.1097/MOG.0b013e32835ff1e9]
4. Larsson SB, Eilard A, Malmström S, Hannoun C, Dhillon AP, Norkrans G, Lindh M. HBsAg quantification for identification of liver disease in chronic hepatitis B virus carriers. Liver Int 2013; Epub ahead of print [PMID: 24118747 DOI: 10.1111/liv.12345]
5. Sonneveld MJ, Zoutendijk R, Janssen HL. Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat 2011; 18: 449-457 [PMID: 21692954 DOI: 10.1111/j.1365-2893.2011.01465.x]
6. Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011; 54: E1-E9 [PMID: 21793018 DOI: 10.1002/hep.24473]
7. Chinese Society of Hepatology. Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhongguo Linchuang Ganranxing Jibing 2011; 4: 1-13
8. Blumberg BS, Alter HJ, Visnich S. A "new" antigen in leukemia sera. JAMA 1965; 191: 541-546 [PMID: 14239025 DOI: 10.1001/jama.1965.03080070025007]
9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/ hep.23190]
10. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283 [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3]
11. Jang JW, Yoo SH, Kwon JH, You CR, Lee S, Lee JH, Chung KW. Serum hepatitis B surface antigen levels in the natural history of chronic hepatitis B infection. Aliment Pharmacol Ther 2011; 34: 1337-1346 [PMID: 22007836 DOI: 10.1111/ j.1365-2036.2011.04888.x]
12. Thompson AJ, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, Slavin J, Bowden S, Gane EJ, Abbott W, Lau GK, Lewin SR, Visvanathan K, Desmond PV, Locarnini SA. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-1944 [PMID: 20512987 DOI: 10.1002/hep.23571]
13. Kim YJ, Cho HC, Choi MS, Lee JH, Koh KC, Yoo BC, Paik SW. The change of the quantitative HBsAg level during the natural course of chronic hepatitis B. Liver Int 2011; 31: 817-823 [PMID: 21645212 DOI: 10.1111/j.1478-3231.2011.02516.x]
14. Takkenberg RB, Jansen L, de Niet A, Zaaijer HL, Weegink CJ, Terpstra V, Dijkgraaf MG, Molenkamp R, Jansen PL, Koot M, Rijckborst V, Janssen HL, Beld MG, Reesink HW. Baseline hepatitis B surface antigen (HBsAg) as predictor of sustained HBsAg loss in chronic hepatitis B patients treated with pegylated interferon-α2a and adefovir. Antivir Ther 2013; 18: 895-904 [PMID: 23639931 DOI: 10.3851/ IMP2580]
15. Hadziyannis E, Hadziyannis SJ. Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility. Expert Rev Gastroenterol Hepatol 2014; 8: 185-195 [PMID: 24417264 DOI: 10.1586/17474124.2014.876362]
16. Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, Manns MP, Wedemeyer H, Naoumov NV. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology 2010; 52: 1611-1620 [PMID: 20931556 DOI: 10.1002/hep.23905]
17. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-143 [PMID: 20955704 DOI: 10.1053/ j.gastro.2010.10.011]
18. Cai W, Xie Q, An B, Wang H, Zhou X, Zhao G, Guo Q, Gu R, Bao S. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients. J Clin Virol 2010; 48: 22-26 [PMID: 20233672 DOI: 10.1016/ j.jcv.2010.02.014]
19. Papatheodoridis G, Goulis J, Manolakopoulos S, Margariti A, Exarchos X, Kokkonis G, Hadziyiannis E, Papaioannou C, Manesis E, Pectasides D, Akriviadis E. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy. J Hepatol 2014; 60: 62-68 [PMID: 24012614 DOI: 10.1016/j.jhep.2013.08.023]
20. Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49: 1151-1157 [PMID: 19115222 DOI: 10.1002/hep.22744]
21. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49: 1141-1150 [PMID: 19338056 DOI: 10.1002/hep.22760]
22. Sonneveld MJ, Zoutendijk R, Flink HJ, Zwang L, Hansen BE, Janssen HL. Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response. Clin Infect Dis 2013; 56: 100-105 [PMID: 23042976 DOI: 10.1093/cid/cis859]
23. Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao JH, Jia JD, Wedemeyer H, Locarnini S, Janssen HL, Marcellin P. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J Hepatol 2011; 55: 1121-1131 [PMID: 21718667 DOI: 10.1016/j.jhep.2011.06.006]
24. Sonneveld MJ, Hansen BE, Piratvisuth T, Jia JD, Zeuzem S, Gane E, Liaw YF, Xie Q, Heathcote EJ, Chan HL, Janssen HL. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013; 58: 872-880 [PMID: 23553752 DOI: 10.1002/hep.26436]
25. Yu HB, Liu EQ, Lu SM, Zhao SH. Treatment with peginterferon versus interferon in Chinese patients with hepatitis B. Biomed Pharmacother 2010; 64: 559-564 [PMID: 20630699 DOI: 10.1016/j.biopha.2010.03.004]
26. Huang Z, Deng H, Zhao Q, Zheng Y, Peng L, Lin C, Zhao Z, Gao Z. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study. Eur J Gastroenterol Hepatol 2013; 25: 1165-1169 [PMID: 23571612 DOI: 10.1097/MEG.0b013e3283612e95]